Menlo Therapeutics to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. MNLO, a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at the following upcoming investor conferences:

• Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 8:00 a.m. ET in New York, New York
• JMP Securities 2019 Life Sciences Conference on Wednesday, June 19, 2019 at 10:00 a.m. ET in New York, New York

The presentations will be webcast live and can be accessed by logging onto the "Investors" section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Replays of the webcast will be archived on the Company's website for 30 days following the presentation.

About Menlo Therapeutics

Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK₁ receptor antagonist, for the treatment of pruritus. The company's clinical development program for serlopitant includes two ongoing Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis, a planned Phase 3 program for the treatment of pruritus associated with psoriasis, and a Phase 2 clinical trial for the treatment of chronic pruritus of unknown origin.

Investor Contact: dsheel@menlotx.com

Media Contact: media@menlotx.com